Tomoyuki Ikeuchi Hirokazu Tokuyasu Soichiro Ishikawa
10.2169/internalmedicine.0927-18
Intern Med
2019;58(1):101-104.
afatinib complete response compound mutation exon 19 deletion exon 20 insertion
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/30606938/
Adenocarcinoma of Lung / drug therapy Afatinib / therapeutic use Antineoplastic Agents / therapeutic use Carcinoma, Non-Small-Cell Lung / drug therapy ErbB Receptors / genetics Exons / genetics Lung Neoplasms / drug therapy
Adenocarcinoma of Lung / drug therapy Afatinib / therapeutic use Antineoplastic Agents / therapeutic use Carcinoma, Non-Small-Cell Lung / drug therapy ErbB Receptors / genetics Exons / genetics Lung Neoplasms / drug therapy Case Reports Adenocarcinoma of Lung / genetics Aged Brain Neoplasms / secondary Carcinoma, Non-Small-Cell Lung / genetics Female Humans Lung Neoplasms / genetics Mutagenesis, Insertional Quinazolines / administration & dosage Sequence Deletion Antineoplastic Agents Quinazolines Afatinib ErbB Receptors
PMC6367085
30606938
Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib
2019